Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial

• Hauptverfasser: Vu Dinh Thiem (Verfasst von), Nguyen Dang Quang (Verfasst von), Nguyen Hai Tuan (Verfasst von), Kyeongmi Cheon (Verfasst von), Nancy Gallagher (Verfasst von), Alain Luxembourg (Verfasst von), Thomas Group (Verfasst von), Cyrus Badshah (Verfasst von)
• Format: Buch
• Veröffentlicht: Taylor & Francis Group, 2021-07-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

This open-label, single-center, Phase 3 study (NCT03546842) assessed the immunogenicity and safety of the nine-valent human papillomavirus (9vHPV; HPV6/11/16/18/31/33/45/52/58) vaccine in Vietnamese males and females, with the aim to support 9vHPV vaccine licensure in Vietnam. Participants aged 9-26...